Latest News

Latest News

OOS Investigation: A Solubility-Related HPLC Assay Failure

OOS Investigation: A Solubility-Related HPLC Assay Failure

A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

read more
Connecting ADME and Mouse Models in Preclinical Oncology

Connecting ADME and Mouse Models in Preclinical Oncology

In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Clinical Trials Roundup | 28 Aug 2026

Clinical Trials Roundup | 28 Aug 2026

Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...

read more
From EHR Data to Real-World Evidence: Health IT Meets R&D

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

read more
Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

read more
Clinical Trials Roundup | 28 Aug 2026

Clinical Trials Roundup | 28 Aug 2026

Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...

read more
From EHR Data to Real-World Evidence: Health IT Meets R&D

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

read more
Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Obesity Drug News: GLP-1 Readouts and Approval Watch

Obesity Drug News: GLP-1 Readouts and Approval Watch

Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...

read more
AI-Discovered Drugs in 2026: The State of Play

AI-Discovered Drugs in 2026: The State of Play

Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...

read more
Weekly News Roundup | 24 August 2026

Weekly News Roundup | 24 August 2026

Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...

read more
The Role of Ambient AI in the Future of Specialty Care

The Role of Ambient AI in the Future of Specialty Care

For over a decade, the administrative burden in specialty medicine has quietly worsened. Orthopedic surgeons doing 40 patients a day are spending more time in the EHR than in the room. Ambient AI scribes have changed that equation in ways that are only beginning to...

read more

Further News

EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint

ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...

Healthcare AI Needs Trusted Evidence and Communication Standards

The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...

Younger TAVR Patients Raise the Bar for Long-Term Valve Performance

As transcatheter aortic valve replacement (TAVR) expands into younger patients with longer life expectancy, the definition of a successful procedure needs to grow with it. A July 2026 international position statement identified this trend as a reason for greater focus...

Biotech Deal Structure: Upfronts, Milestones and Royalties Explained

On 2 October 2026, Novartis agreed to license an autoimmune candidate from Abogen for $575 million upfront. Abogen’s release said milestones could add up to about $7.2 billion if every option is exercised. Many headlines led with the combined figure of about $7.8...

Lower Drug Prices Mean Little If the Medication Can’t Reach the Resident

The debate over prescription drug costs, in long-term care as elsewhere, often starts and ends with a number. How much did the medication cost before a negotiated price? How much will Medicare pay? What will the patient owe at the pharmacy counter? Those are important...

Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag

Vaxcyte reported positive topline results from OPUS-1 on Monday 5 October 2026. The pivotal adult Phase 3 tested VAX-31, the company’s 31-valent pneumococcal conjugate vaccine. It is the first of three adult Phase 3 trials to report. The release was datelined San...

Who Confirms the Alert Before Dawn?

I practice emergency medicine. Overnight care is where timing funds or fails any sepsis early warning tool. A recommendation that sits unconfirmed for hours is not decision support. It is wallpaper. Confirmation is the intervention Accuracy slides still dominate...

The Model Said No. Who Gets to Overrule It?

An AI reading routine biopsy slides separated rare tumor patients on pembrolizumab into groups whose median survival differed fourfold. That is a scientific advance. It is also a potential new gatekeeper, and almost no cancer center has decided who may overrule it.

    Weekly News Roundup | 05 October 2026

    Life science news 5 October 2026: four US approvals, three deals and two UK regulatory items. The FDA approved Emcitate, which it calls the first treatment for MCT8 deficiency. The FDA approved a heart valve that can be expanded as a child grows. AstraZeneca agreed to...

    Novartis Licenses Abogen mRNA-Encoded T-Cell Engager for $575m Upfront

    Novartis has licensed ABO2203, an mRNA-encoded T-cell engager, from Abogen Biosciences for 575 million US dollars upfront and up to 7.2 billion in milestones.

      Why Periodontitis Matters Beyond Dentistry

      In brief: Periodontitis, the advanced form of gum disease, is consistently linked with cardiovascular disease, type 2 diabetes and adverse pregnancy outcomes. Only the diabetes link is supported by treatment trials, in which periodontal therapy lowers HbA1c by about...

      Low FODMAP Diet and Disordered Eating in IBS

      A new study published in September has reinforced how, for people with IBS who have been taught the low FODMAP diet, uncontrolled digestive symptoms and psychological distress can be linked to disordered eating behaviours. It can help us think about how patients are...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.